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ABSTRACT
Gammaherpesviruses establish persistent, systemic infections and cause cancers. Murid herpesvirus 4 (MuHV-4) provides a
unique window into the early events of host colonization. It spreads via lymph nodes. While dendritic cells (DC) pass MuHV-4
to lymph node B cells, subcapsular sinus macrophages (SSM), which capture virions from the afferent lymph, restrict its spread.
Understanding how this restriction works offers potential clues to a more comprehensive defense. Type I interferon (IFN-I)
blocked SSM lytic infection and reduced lytic cycle-independent viral reporter gene expression. Plasmacytoid DC were not re-
quired, but neither were SSM the only source of IFN-I, as IFN-I blockade increased infection in both intact and SSM-depleted
mice. NK cells restricted lytic SSM infection independently of IFN-I, and SSM-derived virions spread to the spleen only when
both IFN-I responses and NK cells were lacking. Thus, multiple innate defenses allowed SSM to adsorb virions from the afferent
lymph with relative impunity. Enhancing IFN-I and NK cell recruitment could potentially also restrict DC infection and thus
improve infection control.
IMPORTANCE
Human gammaherpesviruses cause cancers by infecting B cells. However, vaccines designed to block virus binding to B cells
have not stopped infection. Using a related gammaherpesvirus of mice, we have shown that B cells are infected not via cell-free
virus but via infected myeloid cells. This suggests a different strategy to stop B cell infection: stop virus production by myeloid
cells. Not all myeloid infection is productive. We show that subcapsular sinus macrophages, which do not pass infection to B
cells, restrict gammaherpesvirus production by recruiting type I interferons and natural killer cells. Therefore, a vaccine that
speeds the recruitment of these defenses might stop B cell infection.
Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated her-pesvirus (KSHV) persist in B cells and cause cancers (1). Re-
ducing their B cell infections is therefore an important therapeutic
goal. Limited viral gene expression (2) makes established infec-
tions difficult to clear. The early events of host colonization may
provide better targets. However, control mechanisms must be de-
fined in vivo: inferring mechanisms from in vitro studies has
proven problematic because immune function and its evasion are
context dependent. Thus, EBV gp350-specific antibodies block B
cell infection, and CD8 T cells kill infected B cells in vitro, but
vaccinations to induce these effectors have not reduced infection
rates (3).
The early events of human infections are difficult to analyze
because they predate clinical presentation (4). However, gam-
maherpesviruses long predate human speciation (5), and peak
viral diversity in genes that interact with host-diverse functions
suggests that viral coevolution has since acted to counter host
divergence. Therefore, human and other mammalian gamma-
herpesviruses should colonize their hosts in similar ways. Mu-
rid herpesvirus 4 (MuHV-4) realistically infects laboratory
mice (6) and so can experimentally reveal events of likely rele-
vance to EBV and KSHV. Eighty percent to 90% of its genes
have clear homologs in EBV and KSHV (7), and even where
there is genetic diversity, for example, in CD8 T cell evasion,
function appears to be conserved.
EBV is hypothesized to enter new hosts by infecting B cells.
However, naive B cells rarely meet environmental antigens di-
rectly, with their default response to antigen alone being apoptosis
(8); rather, they meet antigens presented on myeloid cells in
lymph nodes (LN) (9). MuHV-4 host colonization conforms to
this paradigm, with infection first reaching B cells in LN via den-
dritic cells (DC) (10); submucosal lymphoid tissue is colonized
later (11). MuHV-4 exploits myeloid/lymphoid cell contact for
spread (12), making B cell infection difficult to block directly.
However, blocking myeloid infection could potentially restrict B
cell infection indirectly. Viral exploitation of endocytic scavenging
pathways (13, 14) makes myeloid cell entry difficult to block, but
virus production by myeloid cells might be susceptible. Of note,
not all myeloid infection is productive: subcapsular sinus macro-
phages (SSM) communicate with B cells (15) and are infected by
MuHV-4 yet restrict its spread (16). To reveal mechanisms capa-
ble of in vivo infection control, we sought to understand how SSM
restrict MuHV-4 replication.
SSM are specialized sessile macrophages that filter the lymph;
splenic marginal zone (MZ) macrophages (MZM) analogously
filter the blood (17). Slow percolation of the lymph and blood past
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their filtering macrophages promotes pathogen adsorption. A po-
tential hazard is that adsorbed pathogens then replicate in the
filtering macrophages. Host defense against this has been studied
by inoculating murine footpads (intrafootpad [i.f.] inoculation)
with vesicular stomatitis virus (VSV): SSM infection is productive,
but the resulting type I interferon (IFN-I) response protects pe-
ripheral nerves and prevents disease (18). SSM susceptibility yet
neuronal protection suggests that SSM respond weakly to IFN-I,
and weak MZM IFN-I responses are associated with enhanced
immune priming (19). IFN-I responses to vaccinia virus Ankara
also recruit NK cells, although the antiviral efficacy of this re-
sponse was not shown (20).
Extrapolating such results to natural infections is not necessar-
ily straightforward, as most viruses engage in host-specific IFN-I
evasion (21). VSV normally infects cows rather than mice, vac-
cinia virus is not mouse adapted, and the Ankara strain has lost
many immune evasion genes. In contrast, MuHV-4 evasion ap-
pears to be fully functional in laboratory mice (6). Natural
MuHV-4 entry is probably via the upper respiratory tract (22), but
i.f. infection is also productive (16) and allows comparison with
data from other SSM studies. Both intranasal (i.n.) and i.f. inocu-
lations lead to SSM infection that inhibits acute viral spread (16).
MuHV-4 evades IFN-I by targeting interferon regulatory fac-
tor 3 (IRF3) (23), TBK-1 (24), the IFN-I receptor (IFNAR) (25),
STAT-1/2 (26), as well as other pathways (27) and associated de-
fenses such as apoptosis/autophagy (28), NF-B (29), and PML
(30, 31). Nonetheless, disease in IFNAR-deficient mice (32, 33)
indicates IFN-I-dependent restraint. IFN-I reduces MuHV-4 re-
activation from latency in B cells (34), but heightened reactivation
normally attenuates infection (35), and the acute phenotypes of
IFNAR deficiency are more suggestive of increased lytic replica-
tion before B cell colonization. In the spleen, IFN-I restricts
mainly macrophage infection (36). Here we show that IFN-I and
NK cells are key components of the SSM barrier to MuHV-4
spread.
MATERIALS AND METHODS
Mice and immune depletions. C57BL/6J, LysM-cre (37), and CD11c-cre
(38) mice were infected at 6 to 12 weeks of age. Experiments were ap-
proved by the University of Queensland Animal Ethics Committee in
accordance with Australian National Health and Medical Research Coun-
cil guidelines. Virus was given i.f. in 50 l (105 PFU) under isoflurane
anesthesia. Phagocytic cells were depleted by i.f. administration of 50 l
clodronate-loaded liposomes (39) 3 and 5 days before infection, which
was confirmed by CD169 loss around the subcapsular sinus (16). NK cells
were depleted by intraperitoneal (i.p.) administration of 200 g mono-
clonal antibody (MAb) PK136 (anti-NK1.1; Bio-X-Cell) 1 and 3 days
before infection and every 2 days thereafter. Plasmacytoid DC (pDC) were
depleted by i.p. injection of 400g MAb BX444 (anti-CD317; Bio-X-Cell)
1 and 3 days before infection and every 2 days thereafter. IFN-I signaling
was blocked by i.p. injection of 200 g MAb MAR1-5A3 (anti-IFNAR;
Bio-X-Cell) 1 day before infection and every 2 days thereafter. Experi-
mental groups were compared statistically by Student’s two-tailed un-
paired t test.
Cells and viruses. BHK-21 cells and 3T3-50 cells, which express doxy-
cycline-inducible MuHV-4 (MHV) open reading frame 50 (ORF50) (40),
were grown in Dulbecco’s modified Eagle’s medium with 2 mM glu-
tamine, 100 IU/ml penicillin, 100 g/ml streptomycin, and 10% fetal calf
serum (complete medium). MHV-green fluorescent protein (GFP) (41)
expresses GFP from an EF1 promoter between ORFs 57 and 58.
MHV-RG (11) has a viral M3 promoter driving LoxP-flanked mCherry
upstream of GFP between ORFs 57 and 58. Cre switches its fluorochrome
expression irreversibly from mCherry to GFP (MHV-G). Neither
MHV-RG nor MHV-G is attenuated in C57BL/6 mice, and neither virus
outgrows the other in a mixed infection (36). MHV-M50 has 416 bp of the
murine cytomegalovirus (MCMV) IE1 promoter in the 5= untranslated
region of ORF50 exon 1. This deregulates the lytic switch, essentially abol-
ishing viral latency (35). ORF50-negative (ORF50) MuHV-4 has a
1,715-bp deletion in ORF50 exon 2, precluding lytic gene expression with-
out complementation (40). The virus was grown and titers were deter-
mined in 3T3-50 cells with doxycycline (1 g/ml). Other viruses were
grown and titers were determined in BHK-21 cells (42).
Infectivity assays. Infectious virus was quantified by a plaque assay
(42). Virus dilutions were incubated with BHK-21 cells (2 h at 37°C),
overlaid with complete medium– 0.3% carboxymethylcellulose, cultured
for 4 days, fixed (1% formaldehyde), and stained (0.1% toluidine blue) for
plaque counting. Total virus (latent plus infectious) was quantified by an
infectious center (IC) assay (42). Freshly isolated LN or spleen cells were
layered onto BHK-21 cell monolayers and cultured as described above for
plaque assays. To measure Cre-dependent viral fluorochrome switching,
plaque or IC assays were performed at limiting dilution in 96-well plates
(16 wells per dilution). After 4 days, each well was scored under UV illu-
mination for green (GFP positive [GFP], switched) and red (mCherry,
unswitched) fluorescence. Percent switching was calculated as 100 
green titer/(red titer green titer).
Viral genome quantitation. MuHV-4 genomic positions 24832 to
25071 were amplified by PCR (Rotor Gene 3000; Corbett Research)
from 10 ng DNA (NucleoSpin Tissue kit; Macherey-Nagel). PCR prod-
ucts quantified with Sybr green (Invitrogen) were compared to a stan-
dard curve of a cloned template amplified in parallel and distinguished
from paired primers by melting-curve analysis. Correct sizing was
confirmed by electrophoresis and ethidium bromide staining. Cellular
DNA in the same samples was quantified by amplifying a -actin gene
fragment.
Immunostaining. Organs were fixed in 1% formaldehyde–10 mM
sodium periodate–75 mM L-lysine (18 h at 4°C), equilibrated in 30%
sucrose (24 h at 4°C), and then frozen in OCT. Six-micrometer sections
were blocked with 0.3% Triton X-100 –5% donkey serum (1 h at 23°C)
and then incubated (18 h at 4°C) with primary antibodies to GFP (rabbit
polyclonal antibody [PAb] or goat PAb; Abcam), B220 (rat MAb RA3-
6B2; Santa Cruz Biotechnology), NKp46 (rat MAb 29A1.4; BioLegend),
CD11c (hamster MAb N418), CD68 (rat MAb FA-11; Abcam), F4/80 (rat
MAb CI:A3-1; Santa Cruz Biotechnology), mCherry (rabbit PAb; Ba-
drilla), and CD169 (rat MAb 3D6.112; Serotec) and polyclonal rabbit sera
to MuHV-4, raised by subcutaneous virus inoculation. This serum recog-
nizes multiple lytic antigens, including the ORF65 capsid protein, the
gp70 complement control protein, and gp150 (43). Sections were washed
three times in phosphate-buffered saline (PBS); incubated (1 h at 23°C)
with Alexa 568- or Alexa 647-donkey anti-rat IgG PAb, Alexa 488- or
Alexa 568-donkey anti-rabbit IgG PAb (Life Technologies), Alexa 488-
donkey anti-goat PAb, and Alexa 647-donkey anti-hamster IgG PAb (Ab-
cam); washed three times in PBS; stained with 4=,6-diamidino-2-phe-
nylindole (DAPI); and mounted in Prolong Gold (Life Technologies).
Fluorescence was visualized with a Zeiss LSM 510/710 confocal micro-
scope.
Flow cytometry. To identify NK cells, dissociated spleen cells were
blocked with anti-CD16/32 (BD Biosciences) and incubated with bio-
tinylated anti-NKp46 MAb (BioLegend) and then with Alexa 488-conju-
gated streptavidin (Invitrogen). To identify pDC, spleen cells were
blocked with 5% donkey serum and then incubated with antibodies to
CD11c and BST-2 (rabbit PAb; Pierce Biotechnology) or Siglec-H (rat
MAb 440c; Abcam), followed by Alexa 647-donkey anti-hamster IgG PAb
plus Alexa 488-donkey anti-rat PAb or Alexa 488-donkey anti-rabbit PAb
(Life Technologies). Cells were then washed twice in PBS and analyzed on
an Accuri flow cytometer (BD Biosciences).
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RESULTS
IFNAR blockade increases MuHV-4 dissemination via LN. We
hypothesized that SSM are an important site of anti-MuHV-4
action for IFN-I. To test this hypothesis, we gave mice IFNAR-
blocking antibody or not i.p., inoculated them with MuHV-4 by
the i.f. route, and measured virus titers (Fig. 1). IFNAR blockade
significantly increased day 6 titers in popliteal LN (PLN) and
spleens (Fig. 1a). Assays of freeze-thawed samples established that
the increased infection was predominantly latent. IFNAR block-
ade also increased footpad virus titers (Fig. 1b), so as i.f. MCMV
spreads from footpads to PLN to spleen (16), the increased PLN
and spleen titers could potentially have been secondary effects.
However, PLN and spleen titers increased from day 3 to day 6,
whereas footpad titers decreased (Fig. 1c). Therefore, IFN-I inde-
pendently restricted lymphoid infection.
IFNAR blockade increases early LN infection. Increasing
PLN virus titers from day 3 to day 6 implied more B cell prolifer-
ation in IFNAR-blocked mice, as this is how MuHV-4 amplifies its
latent load. Higher titers at day 3, when B cell infection is first
detected (16), suggested that this was due to more initial B cell
infection. PLN titers were also increased at day 1 (Fig. 1d). In-
creased viral genome copy numbers (Fig. 1e) indicated more PLN
FIG 1 IFNAR blockade increases PLN and spleen infections by i.f. MuHV-4. (a) C57BL/6 mice given IFNAR-blocking antibody (IFN) or not (cont) were
infected i.f. with MuHV-4 (105 PFU). Six days later, PLN and spleen viruses were IC assayed for total virus and plaque assayed for infectious virus. Crosses show
means, and other symbols show data for individual mice. IFNAR-blocking antibody increased total but not lytic titers. (b) Mice treated as described for panel a
were plaque assayed 3 and 6 days later for infectious virus in footpads. Bars show means, and diamonds show data for individuals. IFNAR-blocking antibody
increased titers at both time points. (c) Mice treated as described for panel a were IC assayed for reactivatable virus in PLN and spleen 3 and 6 days later. Bars show
means; other symbols show data for individuals. IFNAR-blocking antibody increased infection at both time points in both sites. (d) Mice treated as described for
panel a were tested 1 day later for infectious footpad virus by plaque assay and for reactivatable PLN virus by IC assay. Crosses show means; other symbols show
data for individual mice. IFNAR-blocking antibody increased PLN but not footpad infection. (e) DNA from PLN in panel d was assayed for viral genome load
by quantitative PCR. Viral load (K3) was normalized by cellular load (-actin) for each sample. Crosses show means; other symbols show data for individuals.
IFNAR-blocking antibody increased viral genome loads. (f) Mice were given IFNAR-blocking antibody or not and then latency-deficient MHV-M50 (105 PFU
i.f.). One day later, footpad virus was plaque assayed and PLN virus was IC assayed. Crosses show means; other symbols show data for individuals. IFNAR-
blocking antibody increased PLN but not footpad infection. (g) Mice were depleted of pDC (pDC) or not (cont) by 2 i.p. injections of anti-CD317/BST-2 MAb
(400g/mouse) 48 h apart and then given MHV-GFP i.f. (105 PFU). Three days later, footpad virus was plaque assayed, and PLN virus and spleen virus were IC
assayed. Bars show means; other symbols show data for individual mice. pDC depletion increased footpad but not PLN or spleen infections. Two further
experiments gave equivalent results. (h) pDC depletion efficacy was checked by flow cytometry of gated CD11c spleen cells for the pDC markers Siglec-H and
BST-2. n is the number of cells in the boxed region.
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FIG 2 IFNAR blockade increases SSM infection. (a) Mice given IFNAR-blocking antibody (IFN) or not (cont) were infected i.f. with MHV-GFP (105 PFU).
One day later, PLN sections were stained for viral GFP. Nuclei were stained with DAPI. Gray arrows show example GFP cells in the LN substance. Open arrows
show increased GFP staining around the subcapsular sinus of mice treated with IFNAR-blocking antibody. Each image is representative of data for 6 samples per
group. (b) GFP cells were counted for samples as described for panel a. Bars show group means. Other symbols show mean counts for 3 randomly selected fields
of view per section across 3 sections of individual mice. IFNAR-blocking antibody significantly increased GFP cell numbers. (c) C57BL/6 mice were given
IFNAR-blocking antibody or not and infected or not with MuHV-4 as described for panel a. Six days later, PLN sections were stained for CD169 (SSM) and CD68
(macrophages/DC). Infected mice lost CD169 expression around the subcapsular sinus (arrows), regardless of IFNAR blockade. CD68 staining around the
subcapsular sinus was also reduced. (d) PLN from mice infected as described for panel a were stained 1 day later for GFP plus CD68, CD169, or B220 (B cells).
Arrows show example dual-positive cells. (e) GFP and viral lytic antigen (MHV)-positive cells colocalizing with myeloid cell markers were counted for 3 fields
of view per section across 3 sections for each of 5 mice per group. Bars show group means; other symbols show individual mean counts. IFNAR-blocking antibody
increased GFP and MHV myeloid (CD169 or CD68) cell numbers around the subcapsular sinus. (f) PLN of mice infected as described for panel a were
stained 1 day later for viral GFP and lytic antigens (MHV). MHV expression was minimal in control mice. Arrows show example GFP MHV cells in mice
treated with IFNAR-blocking antibody. Each image is representative of data for 6 samples per group. (g) PLN of mice infected as described for panel a were stained
for viral antigens and cell type markers. Arrows show examples of colocalization. Quantitation was as described for panel e.
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infection and not just more ex vivo reactivation. IFNAR blockade
also increased day 1 PLN infection by MHV-M50. This virus has a
murine cytomegalovirus IE1 promoter inserted into the ORF50 5=
untranslated region, essentially abolishing lymphoproliferation
through forced lytic reactivation (35) (Fig. 1f). Therefore, IFNAR
blockade increased PLN infection before the onset of virus-driven
lymphoproliferation. IFNAR blockade did not significantly in-
crease day 1 footpad infection by either wild-type (WT) or M50
MuHV-4. Therefore, it acted directly on PLN infection.
pDC are nonessential to restrict LN infection. pDC produce
copious amounts of IFN-I (44). To test whether they were re-
quired for IFN-I to restrict MuHV-4 spread, we gave mice a de-
pleting antibody to CD317/tetherin/BST-2, which is expressed
constitutively by pDC and inducibly by other cell types (45) (Fig.
1g and h). This significantly increased day 3 virus titers in footpads
but not in PLN or spleens. Therefore, pDC were nonessential for
IFN-I to restrict acute lymphoid infection.
IFN-I restricts SSM infection. We identified infected cells by
immunostaining of PLN sections for virus-expressed GFP and
lytic antigens (Fig. 2). Low-magnification images at day 1 (Fig. 2a)
showed many more GFP cells around the subcapsular sinus of
IFNAR-blocked mice (Fig. 2b). GFP cell numbers elsewhere in
the PLN remained low.
Inflammation is associated with CD169 SSM displacement
(46). Virus infection ablated CD169 staining at day 6 more dra-
matically (Fig. 2c). The concomitant loss of subcapsular sinus
CD68 expression, which marks macrophages and DC (47), was
consistent with cell displacement or loss. Nonetheless, at day 1,
when CD169 loss was less marked, IFNAR blockade significantly
increased the number of CD68 and CD169 GFP cells around
the subcapsular sinus (Fig. 2d and e). B220 B cells were closely
associated with GFP cells but remained GFP. While most my-
eloid cells express CD68, its restriction to endosomes and lyso-
somes limited detection sensitivity, as these are not always cap-
tured on sections. However, all GFP cells had a myeloid rather
than a lymphoid morphology, and the vast majority (	90%) lo-
calized to the subcapsular sinus. Thus, they appeared to be SSM
and possibly also other myeloid cells, such as dendritic cells, in the
same site.
IFNAR blockade also increased MuHV-4 lytic antigen staining
around the subcapsular sinus (Fig. 2e to g). Lytic antigen and GFP
staining only partly overlapped. GFP was expressed from an EF1
promoter, which operates independently of the viral lytic cycle
(45), so GFP antigen-negative cells may have harbored latent
genomes. The presence of GFP antigen-positive cells indicated
that GFP expression could also be shut off during lytic infection.
No B220 cells were viral antigen positive. Rather, IFNAR block-
ade increased lytic infection in myeloid cells.
IFN-I protects SSM independently of lytic infection. IFN-I
limits protein synthesis and thus should inhibit mainly viral lytic
replication. Increased viral lytic antigen expression in SSM after
IFNAR blockade was consistent with this idea. To test whether
IFN-I could also act before the initiation of lytic infection, we gave
mice anti-IFNAR antibody or not and then infected them by the
i.f. route with MuHV-4 lacking its essential ORF50 lytic transac-
tivator (Fig. 3). ORF50 MuHV-4 does not express new lytic
genes without complementation. Thus, it is limited in vivo to lytic
cycle-independent GFP expression (from an EF1 promoter).
IFNAR blockade again increased GFP expression around the sub-
capsular sinus (Fig. 3a and b) in CD68 and CD169 but not
B220 cells (Fig. 3c). Therefore, IFN-I also restricted SSM infec-
tion before the initiation of lytic gene expression.
Synergistic effects of IFN-I blockade and SSM depletion. To
compare the loss of IFN-I-mediated SSM defense with complete
SSM loss, we gave mice either liposomal clodronate, anti-IFNAR
antibody, both, or neither and then administered MHV-GFP by
the i.f. route (Fig. 4). SSM depletion accelerates the spread of
MuHV-4 to the spleen (16), and both SSM depletion and IFNAR
blockade increased spleen infection after 6 days (Fig. 4a). SSM
depletion and IFNAR blockade together increased both PLN and
spleen infections significantly more than either one did alone.
FIG 3 IFN-I restricts SSM infection independently of viral lytic gene expres-
sion. (a) Mice were given IFNAR-blocking antibody (IFN) or not (cont) and
then given i.f. ORF50 MuHV-4 (105 PFU), which expresses lytic genes only
with complementation. One day later, PLN sections were stained for viral GFP.
Arrows show example GFP cells. Each image is representative of results for 6
samples per group. (b) GFP cells were counted across 3 randomly selected
fields of view per section for 3 sections from each of 6 mice per group. Bars
show group means, and other symbols show mean counts for individuals.
IFNAR-blocking antibody increased GFP cell numbers. (c) PLN of mice
infected as described for panel a were stained for viral GFP plus CD68, CD169,
and B220. Arrows show example dual-positive cells. No B cells were GFP.
Lawler et al.
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Therefore, SSM were not the only source or site of action of IFN-I,
and IFN-I was not the only SSM defense.
Immunostaining of PLN for viral GFP and lytic antigens (Fig.
4b) also showed that SSM depletion and IFNAR blockade addi-
tively increased infection. All mice showed more GFP than viral
antigen-positive cells, and most GFP cells were B220 B cells
(Fig. 4c). Thus, by this time, increased myeloid infection had fed
through to increased B cell infection. The paucity of lytic antigen-
positive cells at day 6 compared to day 3 (Fig. 2e) implied that
other immune defenses had substituted for IFN-I to control lytic
infection.
In spleens, IFNAR blockade and SSM depletion individually
had little effect on GFP or virus-positive cell numbers but to-
gether caused a marked increase (Fig. 4d to f). This applied across
the red pulp, MZ, and white pulp (WP) (Fig. 4e), with WP B cells
being prominently infected (Fig. 4f). i.f. liposomal clodronate
does not deplete MZM (39), so it must have increased virus seed-
ing to the spleen. IFNAR blockade increased SSM infection (Fig.
2), but this evidently entailed exposure to additional immune de-
fenses, so SSM depletion more efficiently seeded PLN virus to the
spleen. However, IFNAR blockade also promotes splenic MZM
infection (38). Thus, together, SSM depletion and IFNAR block-
ade avoided virus holdup in the PLN and increased subsequent
replication in the spleen.
Functional tracking of MuHV-4 replication in SSM. Viral
floxed reporter gene switching can track infection through specific
FIG 4 IFNAR blockade and SSM depletion synergistically disseminate MuHV-4. (a) Mice were given liposomal clodronate to deplete SSM (clod), IFNAR-
blocking antibody (IFN), both treatments (both), or neither treatment (cont) and then given MHV-GFP i.f. (105 PFU). Six days later, footpad virus was plaque
assayed, and PLN and spleen virus were IC assayed. Bars show means, and other symbols show individual titers. All treatments increased footpad and spleen titers;
only dual treatment increased PLN titers. *, P
 0.05; **, P
 0.01; ***, P
 103; ****, P
 104. (b) GFP and viral antigen (MHV)-positive cells were counted
on PLN sections of mice treated as described for panel a. Bars show group means. Other symbols show mean counts for 3 fields of view per section across 3 sections
of each mouse. All treatments increased GFP and MHV cell numbers, although MHV cell numbers were low. (c) Example images from panel b show infected
cells in PLN. Most GFP cells were B220 (B cells, white arrows). Gray-filled arrows show lytically infected cells. (d) GFP and MHV cells were counted on
spleen sections of mice treated as described for panel a. Bars show group means. Other symbols show mean counts for 3 fields of view per section across 3 sections
of individual mice. Only dual treatment (both) increased spleen infection by this measure. (e) Splenic GFP cells were further subdivided by site. Dual treatment
increased infection in the red pulp (RP), MZ, and white pulp (WP). Single treatments had no significant effect. (f) Example images from panel e show infected
B220 cells. Dashed lines correspond to the MZ. White arrows show infected WP B cells. The gray-filled arrow shows a lytically infected cell.
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cell types of Cre-transgenic mice. Cre switches MHV-RG irrevers-
ibly from red (mCherry) to green (GFP) fluorescence. SSM ex-
press LysM (16), so to test whether IFN-I restricts MHV-RG prop-
agation in SSM, we gave IFNAR-blocking antibody or not and
then i.f. MHV-RG to LysM-cre mice (Fig. 5). IFN-I blockade in-
creased day 6 virus titers, most noticeably in spleens (Fig. 5a). It
also significantly increased the proportion of fluorochrome-
switched virus in footpads and PLN, which was otherwise negligi-
ble (Fig. 5b). Occasionally, mice had high levels of splenic virus
switching. This possibly reflected replication in splenic MZM, as
they also express LysM and switch60% of the i.p. virus reaching
splenic B cells (12). The splenic virus of most IFNAR-blocked
mice was unswitched. Therefore, IFNAR blockade increased both
the productivity of LysM cell infection in footpads and PLN and
the rate of infection spread to the spleen but as separate effects:
most virus still reached the spleen via LysM cells.
MuHV-4fluorochromeswitching in infected cells.Viral fluo-
rochrome switching can also be visualized in infected cells. The
M3 promoter driving fluorochrome expression is active mainly in
early/late lytic infection (48–50). IFNAR blockade increased fluo-
rochrome switching at day 6 in PLN and spleen cells of LysM-cre
mice (Fig. 5c and d). In both IFNAR-blocked and control mice,
cellular fluorochrome switching exceeded that of recovered viri-
ons. GFP PLN cells were difficult to type with certainty but ap-
peared to be myeloid, as none were B220 (B cells). CD11c cells
were also unswitched, consistent with few DC expressing LysM
(39). Thus, IFNAR blockade increased viral lytic gene expression
in LysM cells, but LysM cells remained the main source of viral
propagation.
MuHV-4 fluorochrome switching in CD11c-cre mice. We
next tracked MHV-RG replication in CD11c-cre mice (Fig. 6).
Again IFNAR blockade increased virus titers (Fig. 6a), but now it
also significantly increased the switching of virus recovered from
spleens (Fig. 6b). Although the proportion of PLN virus that was
switched was unchanged, PLN-infected cell switching increased
(Fig. 6c and e), and unlike LysM-cre mice, IFNAR-blocked
CD11c-cre mice had GFP PLN B cells (Fig. 6f). These results
were consistent with IFNAR blockade increasing the total amount
of B cell infection but not altering its predominant route, which
was via DC.
IFNAR blockade increased the fluorochrome switching of both
splenic virus (Fig. 6b) and splenic infected cells (Fig. 6c and d).
Most GFP spleen cells were located around WP follicles (Fig. 6g)
and were myeloid (CD11cCD169), although GFPMZ B cells
were also evident (Fig. 6h). Control mice also had GFP myeloid
cells and B cells but fewer (Fig. 6d). Thus, again, IFNAR blockade
increased virus spread but did not alter its predominant route.
NK cells are a second line of SSM defense. The finding that
IFNAR blockade did not increase MuHV-4 passage through SSM
implied additional, IFN-I-independent restriction, before adap-
tive immunity comes into play (51). The important role of NK
cells in controlling murine cytomegalovirus (52) suggested that
they might also control MuHV-4. Although NK cells are activated
by IFN-I (20), IFNAR blockade increased NK cell recruitment to
MuHV-4-infected LN (Fig. 7a and b), implying IFN-I indepen-
dence in this context. To reveal NK cell function, we compared
their depletion with IFNAR blockade: C57BL/6 mice were
given anti-NK1.1 or anti-IFNAR antibody i.p. or left untreated
and then given MHV-GFP i.f. (Fig. 7c and d). After 1 day, both
treatments significantly increased virus titers, with IFNAR
blockade having a greater effect. PLN sections showed more
viral GFP cells after IFNAR blockade and a smaller but still
FIG 5 IFNAR blockade increases virus production in but not transfer from LysM cells. (a) LysM-cre mice were given IFNAR-blocking antibody (IFN) or not
(cont) and then floxed color-switching MHV-RG (105 PFU i.f.). Six days later, virus was plaque assayed (footpads) or IC assayed (PLN and spleens). Horizontal
bars show means. Other symbols show data for individual mice. The dashed line indicates the assay sensitivity limit. IFNAR-blocking antibody increased
infection in footpads and spleens but not PLN. (b) Viruses from panel a were assayed for fluorochrome switching. Bars show means; other symbols show data for
individual mice. IFNAR-blocking antibody increased virus switching in footpads and PLN. ND, not determined, as there was insufficient virus. (c) Tissue sections
of mice infected as described for panel a were analyzed for infected-cell fluorochrome expression. Bars show group means. Other points show means of data for
3 views per section for each of 3 sections per mouse. IFNAR-blocking antibody increased fluorochrome switching in both PLN and spleens. (d) Example PLN
images show unswitched (mCherry, white arrows) but not switched (GFP) CD11c cells in control mice and mice treated with IFNAR-blocking antibody.
Gray arrows show example GFP cells.
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significant increase after NK cell depletion (Fig. 7a and e).
GFP cells of all groups clustered around the subcapsular si-
nus, and many were CD68 and CD169. Thus, NK cell deple-
tion increased SSM infection.
Without IFN-I and NK cells, SSM pass infection to B cells.
SSM attack by NK cells potentially explained the failure of fluoro-
chrome-switched virus to spread in IFNAR-blocked LysM-cre
mice (Fig. 5). To test this hypothesis, we gave LysM-cre mice both
FIG 6 IFNAR blockade increases virus production in and transfer from CD11c cells. (a) CD11c-cre mice were given IFNAR-blocking antibody or not and then
MHV-RG i.f. (105 PFU). Six days later, virus was plaque assayed (footpads) or IC assayed (PLN and spleens). Horizontal bars show means. Other symbols show
data for individual mice. The dashed line indicates the assay sensitivity limit. IFNAR-blocking antibody significantly increased footpad and PLN but not spleen
infections. (b) Viruses from panel a were assayed for fluorochrome switching. Bars show means; other symbols show data for individuals. IFNAR-blocking
antibody significantly increased the switching of virus recovered from spleens. (c) Tissue sections of mice infected as described for panel a were analyzed for
cellular fluorochrome expression. Bars show group means. Other points show mean counts for 3 views per section for 3 sections per mouse. IFNAR-blocking
antibody increased infected-cell switching in both PLN and spleens. (d) Spleens were analyzed further for viral fluorochrome-positive cell types. IFNAR-blocking
antibody increased B220 and CD11c cell switching, although the increase was significant only for CD11c. (e) PLN overview images show more GFP
(switched) cells with IFNAR-blocking antibody, quantitated as described for panel c. Unswitched (mCherry) cell numbers were similar to those of controls. Six
mice per group gave equivalent results. (f) Higher-power images show both switched and unswitched B cells with IFNAR-blocking antibody and only unswitched
B cells in controls. The images are representative of results for 6 mice per group. (g) Spleen overview images show IFNAR-blocking antibody increasing switched
GFP cell numbers in the MZ between WP follicles and the F4/80 red pulp (arrows). Six mice per group gave similar results, quantitated as described for panel
c. (h) Higher-power spleen images show example GFP and mCherry cells. GFP cells were evident in all mice, but IFNAR-blocking antibody gave significantly
more CD11c GFP cells than controls, quantitated as described for panel d.
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NK-depleting and IFNAR-blocking antibodies before infecting
them with MHV-RG. After 4 days, PLN virus titers of antibody-
treated mice exceeded those of controls (Fig. 8a), and 25% of the
recovered virus was fluorochrome switched (Fig. 8b). Spleen virus
titers also increased, with 	50% switching. Virus from footpads
showed negligible switching. Thus, when both IFN-I and NK cells
were disabled, more virus was produced and a greater proportion
passed through LysM cells, presumably SSM. Day 4 would nor-
mally be too early for virus to have passed through MZM (Fig. 5).
Thus, the switching of splenic virus probably reflected seeding
from the PLN, while PLN virus also included seeding from foot-
pads. However, accelerated MZM infection may have contrib-
uted, as SSM and MZM infections are likely to have similar im-
mune restraints.
The greater virus switching of antibody-treated mice argued
that IFN-I and NK cells regulate MuHV-4 production in LysM
cells. However, while PLN sections of antibody-treated mice
showed more GFP cells than those of controls, their GFP/
mCherry cell ratios were similar (Fig. 8c). Therefore, IFN-I and
NK cells also regulated LysM infection. Most fluorochrome-pos-
itive PLN cells were myeloid rather than lymphoid (Fig. 8d and e),
consistent with fluorochrome expression being lytic while B cell
infection was mainly latent (Fig. 2). Nonetheless GFP B cells
(B220) were evident in antibody-treated mice (Fig. 8e and f).
Thus, when IFN-I and NK cells were lacking, SSM passed
MuHV-4 to B cells.
DISCUSSION
Extracellular fluid returning to the blood provides viruses with a
ready-made vehicle of systemic spread. LN are a key checkpoint,
and myeloid cells are the gatekeepers: migratory DC survey cell-
associated antigens, and sessile SSM survey the afferent lymph.
MuHV-4 infects both cell types, but only DC pass infection to B
cells. IFN-I and NK cells protected SSM against productive infec-
tion by virions adsorbed from the lymph. Other innate immune
effectors (53) may also contribute—the immune response is in-
herently multilayered, and with shared induction pathways, indi-
vidual effectors rarely act alone— but IFN-I and NK cells had key
roles.
A previous study of lung infection (54) found no significant
NK cell contribution to MuHV-4 control. However, LN infection
was not measured. The defensive role of NK cells identified here
was consistent with human genetic deficiency phenotypes (55),
prominent NK cell responses to EBV (56), and NK cell-mediated
defense against EBV in chimeric mice (57). Protection by IFN-I
argued against filtering macrophages being deliberately virus per-
missive (19); rather, the immune response consistently inhibits
infection as it escalates from IFN-I to NK cells to adaptive re-
sponses, with each gaining functional prominence if upstream
containment fails.
Host defense against viremia has anatomical as well as func-
tional layers. Most extracellular fluid traverses more than one
FIG 7 IFN-I and NK cells control PLN infection. (a) C57BL/6 mice were given IFNAR-blocking antibody (IFN) or NK-depleting antibody (NK) or left
untreated (cont) and then infected i.f. with MHV-GFP (105 PFU). One day later, PLN sections were stained for viral GFP plus NKp46 NK cells (NK), myeloid
cells (CD68), or SSM (CD169). Nuclei were stained with DAPI. Open arrows show NKp46 NK cells around the subcapsular sinus. Gray-filled arrows show
CD68 and CD169 infected cells. (b) NKp46NK cells were counted on PLN sections of mice treated as described for panel a. Bars show group means. Circles
show mean counts for 3 fields of view per section from 3 sections per mouse. IFNAR-blocking antibody significantly increased NK cell recruitment above
controls, whereas NK depletion significantly reduced it. (c) Spleen cells of mice given anti-NK1.1 depleting antibody (PK136) (200 g/mouse in 2 injections 48
h apart) or not (control) were analyzed 24 h later by flow cytometry for expression of the NK cell marker NKp46. n is the number of cells in the boxed region. (d)
PLN of mice treated as described for panel a were IC assayed for recoverable virus 1 day after i.f. MHV-GFP. Crosses show means; other symbols show data for
individuals. Both NK cell-depleting antibody and IFNAR-blocking antibody increased titers. IFNAR-blocking antibody had a significantly greater effect. (e)
GFP cells on PLN sections described for panel a were counted for 3 views per section across 3 sections per mouse. Circles show mean counts for individuals. Bars
show group means. Both IFNAR-blocking antibody and NK cell-depleting antibody increased GFP cell numbers. IFNAR-blocking antibody had a significantly
greater effect.
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lymph node; for example, footpad-inoculated MuHV-4 passes
from the PLN to the para-aortic LN (16), and splenic MZM
filter the blood. Invasive virus inoculations are often more
pathogenic than mucosal inoculations because they bypass the
outer defenses: i.p. MuHV-4 reaches the spleen directly (12),
and in this context, IFNAR blockade greatly increases macro-
phage infection (36), consistent with IFNAR/ mice suc-
cumbing more rapidly to i.p. than to i.n. infection (32, 33).
Although invasive inoculations cause more disease, host colo-
nization is not necessarily enhanced, as viral genes now operate
outside their normal evolutionary context. Thus, protecting
against disease after an invasive inoculation is not the same as
protecting against natural infection. For example, recombinant
gp350 protected tamarins against EBV-induced disease but did
not prevent natural human infection (3). Such outcomes em-
phasize the need to develop vaccine strategies that allow for
viral immune evasion.
Natural MuHV-4 infection is probably nasal (22); we studied
i.f. infection because the complexity of i.n. infection makes pri-
mary and secondary LN effects difficult to separate, but the SSM
barrier is relevant to both (16), and increased spleen infection by
i.n. MuHV-4 in IFNAR/mice (33) is consistent with IFN-I also
restricting MuHV-4 passage through mucosa-associated LN.
When the host response meets viral evasion, the outcome can
depend on cell type, and IFN-I and NK cells evidently restricted
MuHV-4 less in DC than in SSM. Most DC infection is initially
latent (58). It may become lytic in vivo only after DC have mi-
grated away from inflammatory infection sites and IFN-I signal-
ing has subsided. Migratory DC may also be less IFN-I responsive
than SSM (59). Nonetheless, antiviral states are inducible, and
vaccine-primed T cells could potentially recruit IFN-I and NK cell
responses upon virus challenge. CD4 T cells control long-term
MuHV-4 infection (60), interact with LN DC (61), and protect via
IFN-II (62), which potentiates IFN-I (63). The efficacy of innate
immunity in restricting SSM infection suggested that recruitment
of these defenses might also be able to limit DC infection and thus
reduce host colonization.
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